中国医药子公司达比加群酯胶囊获得药品注册证书

Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical (600253) has received two drug registration certificates for Dabigatran Etexilate capsules from the National Medical Products Administration [1] Group 1: Product Approval - Tianfang Pharmaceutical received approval for two specifications of Dabigatran Etexilate capsules: 150mg and 110mg [1] - Dabigatran Etexilate is a direct thrombin inhibitor used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation [1] Group 2: Indications and Uses - The drug is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) [1] - It is also used to lower the risk of recurrence of DVT and PE, as well as for the prevention of DVT and PE following hip replacement surgery [1]